Mark Dornan
Chief Executive Officer Alpha-9 Oncology
Mark Dornan is Vice President of Pharmaceutical Development and External Manufacturing at Alpha-9 Oncology, where he leads cross-functional CMC development and manufacturing strategy for radiopharmaceutical programs. He has more than a decade of experience spanning radiochemistry, process and analytical development, GMP manufacturing, CMC regulatory strategy, and the development of innovative oncology therapies from early development through clinical translation. Prior to joining Alpha-9 Oncology, Mark held roles at Eli Lilly, POINT Biopharma, and Dana-Farber Cancer Institute. He holds a Ph.D. in Chemistry from the University of Ottawa and completed a postdoctoral fellowship in radiochemistry at Université de Montréal.
Seminars
- Evaluating how expertise in isotopes, development and validation, quality assurance, production, supply chain, and regulatory readiness should influence CDMO selection decisions across different stages of TRP development
- Assessing and addressing the operational risks associated with tech transfer and batch reproducibility when partnering with external manufacturing providers
- Determining which strategic considerations including scalability, geographic footprint, and isotope supply integration are most critical for supporting future clinical and commercial growth
